A new 5-MeO-DMT trial raises questions about how much psychotherapy adds to psychedelic-assisted treatment for depression and trauma-related symptoms

5-MeO-DMT treatment is prompting a new debate over how much psychotherapy is necessary for meaningful clinical benefit in psychedelic-assisted care. A recent trial centers on whether rapid improvements in depression and trauma-related symptoms can occur with minimal therapeutic support, challenging assumptions that intensive talk therapy is always the active ingredient. The findings matter because psychedelic treatment models are expensive, hard to scale, and often built around many hours of preparation and integration. If a strong share of benefit comes from the pharmacological and acute experiential effects of 5-MeO-DMT itself, shorter and simpler care pathways could become more accessible. The open question is not whether support matters, but which kinds of support matter most, for whom, and at what dose of therapy. That distinction has direct implications for safety, cost, training, trial design, and the future definition of psychedelic-assisted therapy as a clinical model.